StoneX Group’s Tonix Pharmaceuticals TNXP Stock Holding History

StoneX Group’s Portfolio TNXP Stock Details TNXP Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q1	–	Sell	-1	Closed	-$4.96K	–	660
2022 Q4	$4.96K	Buy	+1	New	+$8.63K	﹤0.01%	496

Other funds holding TNXP

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

TCM

Tang Capital Management San Diego, California $1.97B AUM 125.1% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

RJA

Raymond James & Associates St Petersburg, Florida $164B AUM 33.91% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return

StoneX Group's TNXP Position: Q1 2023 in Review

StoneX Group sold out of Tonix Pharmaceuticals (TNXP) in Q1 2023, closing a stake of 1 share — an estimated $4.96K sold.

StoneX Group first reported a position in TNXP in Q4 2022 and held it in 1 quarter. The position peaked at $4.96K in Q4 2022. 18 funds tracked by Wall St. Rank hold TNXP as of Q1 2023.

StoneX Group reported no remaining Tonix Pharmaceuticals position as of Q1 2023 after selling out during the quarter.
StoneX Group sold 1 Tonix Pharmaceuticals share in Q1 2023, an estimated $4.96K.
StoneX Group first reported a position in Tonix Pharmaceuticals in Q4 2022 and held it in 1 quarter.
StoneX Group's Tonix Pharmaceuticals position peaked at $4.96K in Q4 2022.
18 funds tracked by Wall St. Rank held Tonix Pharmaceuticals as of Q1 2023.

Based on StoneX Group's 13F filing for Q1 2023, filed 11 May 2023.